Tissue reactions to bacteria-inoculated rat lead samples. II. Effect of local gentamicin release through surface-modified polyurethane tubing.
A surface modification technique was developed to achieve controlled release of gentamicin from implanted polyurethane (PU) rat lead samples. PU tubing first was provided with an acrylic acid/acrylamide copolymer surface graft and then loaded with gentamicin. This surface modification technique resulted in release of gentamicin base (GB) and was applied either to the inner luminal surface only (PU-GB-1x) or to both the inner and outer surfaces (PU-GB-2x). First we investigated whether the early tissue response was harmfully compromised when surface-modified rat lead samples were implanted without any infectious challenge. Additionally, the efficacy of this type of local gentamicin therapy was investigated by establishing its effect on tissue response and its ability to prevent lead-related infections after inoculation with Staphylococcus aureus. It was demonstrated that the applied surface modification(s) did not induce adverse effects although an increase in the infiltration of granulocytes and macrophages and an increase in the formation of wound fluid and fibrin were observed. This effect was stronger with PU-GB-2x than with PU-GB-1x. With bacterial inoculation the applied surface modification successfully suppressed the infectious challenge, PU-GB-2x more effectively than PU-GB-1x. PU-GB-2x also was more effective when compared to the gentamicin-delivery methods discussed in the first part of this two-part study, i.e., release through a vicinal gentamicin-containing collagen sponge and preoperative gentamicin solution-dipping of rat lead samples.
van Wachem
P B
PB
Groningen University, Laboratory for Cell Biology and Electron Microscopy, The Netherlands.
van Luyn
M J
MJ
de Wit
A W
AW
Raatjes
D
D
Hendriks
M
M
Verhoeven
M L
ML
Cahalan
P T
PT
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004343:Drug Implants; D004567:Electrodes, Implanted; D005839:Gentamicins / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology; D011140:Polyurethanes; D016459:Prosthesis-Related Infections / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D012867:Skin / Q000473:pathology; D013203:Staphylococcal Infections / Q000382:microbiology / Q000517:prevention & control; D013499:Surface Properties
D000900:Anti-Bacterial Agents; D004343:Drug Implants; D005839:Gentamicins; D011140:Polyurethanes